Description:
Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephropathy and cardiac disease. It was developed by Pfizer and was terminated in clinic phase 2 trials.
- Molecular Weight: 419.38
- Molecular Formula: C19H12F3N3O3S
Purity: 95%
Canonical SMILES:
C1=CC=C2C(=C1)C(=NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F)CC(=O)O
InChI:
InChI=1S/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)
InChIKey: BCSVCWVQNOXFGL-UHFFFAOYSA-N
- Boiling Point: 598.7±60.0 °C | Condition: Press: 760 Torr
- Melting Point: 197-198 °C
- Solubility: DMSO: ≥20 mg/mL
- Appearance: Off white to light brown powder
- Application: Zopolrestat is used for the treatment of diabetic nephropathy and cardiac disease.
- Storage: 2-8°C
Synonyms:
3-[(5-Trifluoromethyl-2-benzothiazolyl)methyl]-3,4-dihydro-4-oxophthalazine-1-acetic acid;CP-73850;3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid;Alond;Xedia;2-[4-Oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid;CP 73850; CP73850; CP-73850; Zopolrestat; Zopolrestatum
More details are to be found on supplier website
